Tasly Pharmaceutical International

Tasly Pharmaceutical International is the global division of Tasly Pharmaceutical Group, a leading healthcare enterprise headquartered in Tianjin, China, dedicated to the modernization of Traditional Chinese Medicine (TCM). The company is renowned for its proprietary Dropping Pill technology, which transforms botanical extracts into standardized, high-bioavailability micro-pellets. Its flagship product, Dantonic (T89), is a botanical drug for chronic stable angina that has completed significant global Phase 3 clinical trials, marking a milestone for TCM in Western regulatory pathways. Beyond botanical medicine, Tasly has expanded its portfolio into biologics and chemical drugs through internal R&D and strategic international partnerships. The company operates a comprehensive value chain including cultivation, R&D, manufacturing, and a global distribution network spanning Asia, Africa, and North America.